Last Updated : May 13, 2025
Details
Generic Name:
risperidone
Project Status:
Active
Therapeutic Area:
Schizophrenia, adults
Manufacturer:
Teva Canada Innovation
Call for patient/clinician input open:
Brand Name:
TBC
Project Line:
Reimbursement Review
Project Number:
SR0811-000
Call for patient/clinician input closed:
NOC Status at Filing:
Pre NOC
Biosimilar:
No
Manufacturer Requested Reimbursement Criteria1:
For the treatment of schizophrenia in adults.
Submission Type:
Initial
Submission Complexity:
Tailored Review
Fee Schedule:
Schedule C
Indications:
For the treatment of schizophrenia in adults.
- The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of Canada's Drug Agency. Reimbursement criteria from Canada's Drug Agency will be documented in the final recommendation, if applicable.
| Call for patient/clinician input open | August 30, 2023 |
|---|---|
| Call for patient/clinician input closed | October 24, 2023 |
| Clarification: - No patient input submission received | |
| Submission received | October 13, 2023 |
| Submission accepted | October 27, 2023 |
| Review initiated | October 30, 2023 |
| Draft CADTH review report(s) provided to sponsor for comment | February 01, 2024 |
| Deadline for sponsors comments | February 12, 2024 |
| Clarification: - Submission temporarily suspended - Additional information has been received and the temporary suspension of the review has been lifted | |
| CDA-AMC review report(s) and responses to comments provided to sponsor | June 13, 2025 |
| Expert committee meeting (initial) | June 25, 2025 |
| Draft recommendation issued to sponsor | July 08, 2025 To July 10, 2025 |
| Draft recommendation posted for stakeholder feedback | July 17, 2025 |
| End of feedback period | July 31, 2025 |
Last Updated : May 13, 2025